Lineage Cell Therapeutics appoints Jill A. Howe as CFO effective Nov 14, 2022

Lineage Cell Therapeutics, Inc.

Ms. Howe will receive an annual salary of $415,000 and a $50,000 sign-on bonus.
She is eligible for an annual bonus targeted at 40% of salary and granted a stock option for 1,000,000 shares.
Her prior roles include CFO of DTx Pharma, VP Finance at Gossamer Bio (GOSS), and controller at Amplyx.
CEO Brian Culley and Sr. Director Alexandra Hernandez will step down from interim CFO and principal accounting officer roles.
Ms. Howe also serves on boards of Biora Therapeutics (BIOR) and Codagenix Inc.

item 5.02

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Jill A. Howe

Chief Financial Officer

LCTX · Lineage Cell Therapeutics, Inc.

Effective: 2022-11-14
Filed: October 31, 2022, 7:59 PM ET

On October 28, 2022, Lineage Cell Therapeutics, Inc. (“Lineage,” “we,” “us,” “our,” or the “Company”) appointed Jill A. Howe as its Chief Financial Officer, effective November 14, 2022.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 1.0

Jill A. Howe was appointed as Chief Financial Officer at Lineage Cell Therapeutics, Inc..

Action: appointed
Role: Chief Financial Officer

Exact text from the filing

On October 28, 2022, Lineage Cell Therapeutics, Inc. (“Lineage,” “we,” “us,” “our,” or the “Company”) appointed Jill A. Howe as its Chief Financial Officer, effective November 14, 2022.

View on SEC.gov

Lineage Cell Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001493152-22-029913

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.